Judith Hasko advises life sciences companies and investors on a wide range of technology-based commercial matters. Widely recognized for her market-leading transactional work, she currently serves as Vice Chair of Latham’s Healthcare & Life Sciences Practice.
Ms. Hasko represents companies developing biotechnology, pharmaceutical, medical device and diagnostic products, and their investors on matters, including:
- Licensing and corporate partnering
- Joint ventures
- Co-promotion arrangements
- Manufacturing and distribution agreements
- Asset purchases
- Royalty stream purchases and sales
Ms. Hasko brings complementary business and scientific perspectives to her legal representations. She is a Certified Licensing Professional (CLP), and a member of the Patent Bar. Prior to attending law school, she was part of Genentech’s cardiovascular research department.
She has co-authored several scientific publications and frequently lectures on life sciences commercial topics in both industry and academic settings, including at Berkeley Law and Stanford University.
Ms. Hasko's representative transactions include advising:
- Daiichi Sankyo in a US$6.9 billion oncology collaboration with AstraZeneca in 2019.
- Novan in an exclusive license agreement with Sato Pharmaceutical to grant exclusive rights to develop and commercialize in Japan Novan's topical nitric oxide-releasing product candidate SB204, which was named a 2017 LMG Life Sciences Impact Case of the Year
- Juno Therapeutics in its landmark investment and collaboration with Celgene to develop CAR-T and TCR products, valued at more than US$1 billion. The transaction earned the Thomson Reuters Allicense 2015 Breakthrough Award and LMG Life Sciences Collaboration Impact Deal of the Year for 2015.
- OncoMed in a collaboration with Celgene, valued at more than US$3.3 billion, which received the In Vivo Alliance of the Year Award for 2013.
- Prothena Biosciences and Neotope Biosciences in a license, development, and commercialization agreement with F. Hoffmann-La Roche and Hoffmann-La Roche, to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease.
- OncoMed in its collaboration with Bayer Schering Pharma, valued at more than US$1.4 billion, which received the BayBio Pantheon 2010 DiNA Award.